*These statements have not been evaluated by the Food and Drug Authority, This product is not intended to diagnose, treat, cure or prevent any disease
There is a wide range of cardioprotective benefits to GLP-1R agonists in addition to their metabolic effects on blood glucose, adiposity, serum lipids, and blood pressure [31]
Short-acting agents slow down the stomach more than long-acting ones, though both types affect how we digest food
Cervical fat deposition narrows the upper airway and increases collapsibility, while abdominal fat accumulation limits diaphragmatic movement, reduces lung volume, and compromises airway stability under negative pressure
Azevedo, C
However, compounded GLP-1 medications may not be FDA-approved, and the FDA has warned about adverse events in some compounded semaglutide cases